NIH R01 · 2024
CRCNS: Following the BOLD lightening at rest strikes the seizure onset zone!
Epilepsy is a devastating disease affecting over 50 million people worldwide (WHO). About 30% of patients do not respond positively to medication and are diagnosed as having drug resistant epilepsy (DRE). DRE causes significant costs, morbidity, and mortality. The most effective treatment is to surgically remove the seizure onset zone (SOZ), the region from which seizure activity is triggered. The localization of the SOZ is essential for surgical success. Unfortunately, surgical success rates range from 30%-70% because there is no reliable biomarker of the SOZ. We propose to develop a combined intracranial EEG-fMRI biomarker of the SOZ while the patient is not seizing or at “rest”. One may…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.